MAO inhibitors: Risks, benefits, and lore

Cleveland Clinic Journal of Medicine

Volumn 77, Issue 12, 2010, Pages 859-882

  Wimbiscus, Molly ^a   Kostenko, Olga ^a   Malone, Donald ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; SELEGILINE; TYRAMINE;

ARTICLE; BLOOD PRESSURE; CHEESE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEEDING BEHAVIOR; FOOD DRUG INTERACTION; HEART MUSCLE; HUMAN; HYPERTENSION; INTRADERMAL DRUG ADMINISTRATION; MAJOR DEPRESSION; RISK FACTOR;

ADMINISTRATION, CUTANEOUS; ANTIDEPRESSIVE AGENTS; BLOOD PRESSURE; CHEESE; DEPRESSIVE DISORDER, MAJOR; FOOD HABITS; FOOD-DRUG INTERACTIONS; HUMANS; HYPERTENSION; MONOAMINE OXIDASE INHIBITORS; MYOCARDIUM; RISK FACTORS; SELEGILINE; TYRAMINE;

EID: 78650364351     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.77a.09103     Document Type: Article

References (72)

1. EMSAM, Selegiline Transdermal System. NDA 21,336/21,708. Psychopharmacologic Drugs Advisory Committee. October 26, 2005. www.fda.gov/ohrms/dockets/AC/05/briefng/2005-4186B2_01_01_Somerset-EMSAM.pdf. Accessed October 28, 2010.
2. Patkar AA, Pae CU, Masand PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr 2006; 11:363-375.
3. World Health Organization. Depression. www.who.int/mental_health/management/depression/defnition/en/. Accessed October 28, 2010.
4. Compton WM, Conway KP, Stinson FS, Grant BF. Changes in the prevalence of major depression and comorbid substance use disorders in the United States between 1991-1992 and 2001-2002. Am J Psychiatry 2006; 163:2141-2147.
5. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593-602.
6. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28-40.
7. Balon R, Mufti R, Arfken CL. A survey of prescribing practices for monoamine oxidase inhibitors. Psychiatr Serv 1999; 50:945-947.
8. Clary C, Mandos LA, Schweizer E. Results of a brief survey on the prescribing practices for monoamine oxidase inhibitor antidepressants. J Clin Psychiatry 1990; 51:226-231.
9. Shulman KI, Fischer HD, Herrmann N, Huo CY, Anderson GM, Rochon PA. Current prescription patterns and safety profle of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults. J Clin Psychiatry 2009; 70:1681-1686.
10. Horwitz D, Lovenberg W, Engelman K, Sjoerdsma A. Monoamine oxidase inhibitors, tyramine, and cheese. JAMA 1964; 188:1108-1110.
11. Asatoor AM, Levi AJ, Milne MD. Tranylcypromine and cheese. Lancet 1963; 2:733-734.
12. Gordon MN, Muller CD, Sherman KA, Morgan DG, Azzaro AJ, Wecker L. Oral versus transdermal selegiline: antidepressant-like activity in rats. Pharmacol Biochem Behav 1999; 63:501-506.
13. Lotufu-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaro-mine for the treatment of depression. Neuropsychopharmacology 1999; 20:226-247.
14. Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract 2004; 10:239-248.
15. Evans DL, Davidson J, Raft D. Early and late side effects of phenel-zine. J Clin Psychopharmacol 1982; 2:208-210.
16. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61(suppl 11):37-41.
17. Rabkin J, Quitkin F, Harrison W, Tricamo E, McGrath P. Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study. J Clin Psychopharmacol 1984; 4:270-278.
18. Gomez-Gil E, Salmeron JM, Mas A. Phenelzine-induced fulminant hepatic failure. Ann Intern Med 1996; 124:692-693.
19. Lavin MR, Mendelwitz A, Kronig MH. Spontaneous hypertensive reactions with monoamine oxidase inhibitors. Biol Psychiatry 1993; 34:146-151.
20. Fallon B, Foote B, Walsh BT, Roose SP. "Spontaneous" hypertensive episodes with monoamine oxidase inhibitors. J Clin Psychiatry 1988; 49:163-165.
21. Linet LS. Mysterious MAOI hypertensive episodes. J Clin Psychiatry 1986; 47:563-565.
22. Fisher P. Serotonin syndrome in the elderly after antidepressive monotherapy. J Clin Psychopharmacol 1995; 15:440-442.
23. Sternback H. The serotonin syndrome. Am J Psychiatry 1991; 148:705-713.
24. Thase M. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression. J Clin Psychiatry 2006; 67:671-672.
25. Lee KC, Chen JJ. Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2007; 3:527-537.
26. Cooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry Suppl 1989; Oct (6):38-45.
27. Mallinger AG, Smith E. Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacol Bull 1991; 27:493-502.
28. Fulton B, Benfeld P. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs 1996; 52:450-474.
29. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry 2001; 62(suppl 18):12-17.
30. Gitlin MJ. Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome. J Clin Psychopharmacol 1997; 17:66-67.
31. Szuba MP, Hornig-Rohan M, Amsterdam JD. Rapid conversion from one monoamine oxidase inhibitor to another. J Clin Psychiatry 1997; 58:307-310.
32. Lorenz RA, Vandenberg AM, Canepa EA. Serotonergic antidepres-sants and linezolid: a retrospective chart review and presentation of cases. Int J Psychiatry Med 2008; 38:81-90.
33. Miller DG, Lovell EO. Antibiotic-induced serotonin syndrome. J Emerg Med 2008, May 1 (Epub ahead of print).
34. Das PK, Wakentin DI, Hewko R, Forrest DL. Serotonin syndrome after concomitant treatment with linezolid and meperidine. Clin Infect Dis 2008; 46:264-265.
35. Packer S, Berman SA. Serotonin syndrome precipitated by the mono-amine oxidase inhibitor linezolid. Am J Psychiatry 2007; 164:346-347.
36. Diamond S. The use of sumatriptan in patients on monoamine oxidase inhibitors. Neurology 1995; 45:1039-1040.
37. Fox AW. Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. Headache 2010; 50:249-255.
38. Folks DG. Monoamine oxidase inhibitors: reappraisal of dietary consideration. J Clin Psychopharmacol 1983; 3:249-252.
39. Gardner DM, Shulman KI, Walker SE, Tailor SA. The making of a user friendly MAOI diet. J Clin Psychiatry 1996; 57:99-104.
40. Sweet RA, Brown EJ, Heimberg RG, et al. Monoamine oxidase inhibitor dietary restrictions: what are we asking patients to give up? J Clin Psychiatry 1995; 56:196-201.
41. Shulman KI, Walker SE. Refning the MAOI diet: tyramine content of pizzas and soy products. J C lin Psychiatry 1999; 60:191-193.
42. Azzaro AJ, Vandenberg CM, Blob LF, et al. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. J Clin Pharmacol 2006; 46:933-944.
43. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl 1993; Sep (21): 30-34.
44. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 1986; 17:87-95.
45. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988; 45:129-137.
46. Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry 2007; 68(suppl 8):35-41.
47. Rapaport MH, Thase ME. Translating the evidence on atypical depression into clinical practice. J Clin Psychiatry 2007; 68:e11.
48. Liebowitz MR. Depression with anxiety and atypical depression. J Clin Psychiatry 1993; 54(suppl):10-14.
49. Stewart JW, McGrath PJ, Quitkin FM, et al. Chronic depression: response to placebo, imipramine, and phenelzine. J Clin Psychopharmacol 1993; 13:391-396.
50. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993; 150:118-123.
51. Zarate CA Jr, Tohen M, Baraibar G, Kando JC, Mirin J. Prescribing trends of antidepressants in bipolar depression. J Clin Psychiatry 1995; 56:260-264.
52. Mallinger AG, Frank E, Thase ME, Barwell MM, Diazgranados N, Luckenbaugh DA, Kupfer DJ. Revisiting the effectiveness of standard antidepressants in bipolar disorder: are monoamine oxidase inhibitors superior? Psychopharmacol Bull 2009; 42:64-74.
53. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 2000; 14:3-20.
54. Liebowitz MR, Hollander E, Schneier F, et al. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr Scand Suppl 1990; 360:29-34.
55. Davidson JR, Giller EL, Zisook S, Overall JE. An effcacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. Arch Gen Psychiatry 1988; 45:120-127.
56. Razani J, White KL, White J, et al. The safety and effcacy of combined amitriptyline and tranylcypromine antidepressant treatment: a controlled trial. Arch Gen Psychiatry 1983; 40:657-661.
57. Thase ME, Triverdi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995; 12:185-219.
58. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000.
59. Parker G, Crawford J. Atypical depression: retrospective self-reporting of treatment effectiveness. Acta Psychiatr Scand 2009; 120:213- 221.
60. Henkel V, Mergl R, Algaier AK, Kohnen R, Moller HJ, Hergerl U. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res 2006; 141:89-101.
61. Rothschild R, Quitkin HM, Quitkin FM, et al. A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives. Int J Eat Disord 1994; 15:1-9.
62. Paykel ES. Achieving gains beyond response. Acta Psychiatr Scand Suppl 2002; 12-17.
63. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first life-time major depressive episode herald a chronic course of illness? Am J Psychiatry 2000; 157:1501-1504.
64. Murphy JM, Monson RR, Olivier DC, Sobol AM, Leighton AH. Affective disorders and mortality: a general population study. Arch Gen Psychiatry 1987; 44:473-480.
65. Thase ME, Frank E, Mallinger AG, Hamer T, Kupfer DJ. Treatment of imipramine-resistant recurrent depression, III: effcacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992; 53:5-11.
66. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: a double blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992; 149:195-198.
67. Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry 1990; 47:935-941.
68. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148:910-916.
69. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002; 159:1869-1875.
70. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003; 64:208-214.
71. Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 2006; 26:579-586.
72. Feiger AD, Rickels K, Rynn MA, et al. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, doubleblind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry 2006; 67:1354-1361.